Abstract
Canadian Agency for Drugs and Technologies in Health (CADTH) has no established incremental cost-effectiveness ratio (ICER) threshold for reimbursement purposes. However, a willingness to pay (WTP) threshold of $50,000 per Quality Adjusted Life Year (QALY) is viewed favourably for both oncology and non-oncology products. We aimed to review the submissions of cancer drugs made to CADTH from January 2016 to June 2021, to understand the applicability of willingness to pay thresholds acceptable for CADTH.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
